KFF: Aduhelm Could Lead To Higher Part B Premiums, State Spending

By John Wilkerson / June 11, 2021 at 5:55 PM
The new Alzheimer’s drug Aduhelm could lead to higher Part B premiums for beneficiaries in both Medicare Advantage and fee-for-service, and state and federal spending on Medicaid will likely also rise, according to the Kaiser Family Foundation. It’s difficult to predict how many Alzheimer’s patients will take Aduhelm. Medicare could use a national coverage policy to restrict coverage. That would take time to put in place, and until then, Medicare Advantage plans and the contractors that make regional coverage decisions...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.